Summary of COVID-19 ramipril studies
Hide extended summaries
RCT 114 non-critically ill COVID-19 patients in the USA showing no significant differences with ramipril treatment.
Aug 2023, Advances in Therapy, https://link.springer.com/10.1007/s12325-023-02618-7, https://c19p.org/huang18
1. Huang et al., Ramipril for the Treatment of COVID-19: RAMIC, a Randomized, Double-Blind, Placebo-Controlled Clinical Trial
114 patient ramipril late treatment RCT: 144% higher mortality (p=1), 289% higher ventilation (p=1), 289% higher ICU admission (p=1), and 144% lower hospital discharge (p=1).RCT 114 non-critically ill COVID-19 patients in the USA showing no significant differences with ramipril treatment.
Aug 2023, Advances in Therapy, https://link.springer.com/10.1007/s12325-023-02618-7, https://c19p.org/huang18
Please send us corrections, updates, or comments.
c19early involves the extraction of 200,000+ datapoints from
thousands of papers. Community updates
help ensure high accuracy.
Treatments and other interventions are complementary.
All practical, effective, and safe
means should be used based on risk/benefit analysis.
No treatment or intervention is 100% available and effective for all current
and future variants.
We do not provide medical advice. Before taking any medication,
consult a qualified physician who can provide personalized advice and details
of risks and benefits based on your medical history and situation. IMA and WCH
provide treatment protocols.
Thanks for your feedback! Please search before submitting papers and note
that studies are listed under the date they were first available, which may be
the date of an earlier preprint.